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The proportion of individuals diagnosed with diabetes mellitus is increasing throughout the world, which sequentially drives upward the global frequency 
of diabetic kidney disease (1,2). Diabetes is a costly and 
deadly disease. Patients with diabetic kidney disease are 
at an increased risk for cardiovascular disease, premature 
death, and other severe diseases that ensue in increased 
health-care utilization and frequent hospitalizations (1,2). 
In fact, type II diabetes mellitus is an ongoing medical 
dilemma that clinicians deal with on a daily basis and the 
need for treating diabetes sufficiently is essential because 
of the many complications and comorbidities associated 
with uncontrolled diabetes (1,2).
 Present modalities focus on controlling hyperglycemia and 
high blood pressure with the specific use of angiotensin 
receptor blockers or renin-angiotensin system inhibitors. 
Although such measures diminish the risk of progressive 
renal disease, diabetic kidney disease remains the leading 
cause of end-stage renal disease and the major risk amplifier 
for mortality in this group of patients (1-4). Hence, new 
therapeutic interventions based on new findings of the 
pathophysiology of this disease are necessary.
The preservation of normal metabolism and body defenses 
depends on the balance between cellular antioxidant 
and anti-inflammatory factors. This balance can be 
interrupted by agents and mechanisms in the extracellular 
milieu that induce additional reactive oxygen species and 
inflammation (2-5).
Advanced glycation end-products, are formed both inside 
and outside of the body. Specifically, they originate from 
glycation reaction, which mentions to the addition of a 
carbohydrate to a protein without the participation of an 
enzyme. Glucose is able to bind with proteins in a process 
named glycation, making less pliable, cells stiffer and more 
prone to damage and premature aging (3-6).
Advanced glycation end-products, are elements that 
can be a factor in the development or deteriorating 
of various diseases, likediabetes, chronic renal failure 
and atherosclerosis (2-5). In fact, the cytopathic effect 
of advanced glycation end-products, acts as a major 
environmental factor that causes excess reactive oxygen 
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Recent clinical and preclinical investigations have 
detected glucose and lipid-lowering effects of sevelamer, 
which imply the role of this drug in the treatment of 
type II diabetic patients. 
species or inflammationwhich induce chronic renal 
failure or type II diabetes. In diabetic patients, the raised 
advanced glycation end products levels can also contribute 
to the excessive cardiovascular disease in this population, 
by stimulating oxidant stress and chronic vascular 
inflammation. Various investigations, had revealed that 
sevelamer binds advanced glycation end products in vitro 
in a pH dependent manner (3-7). 
Advanced glycation end products may be of significant 
importance in the development and progression of chronic 
renal failure in type II diabetes, while type 2 diabetes 
mellitus patients with increased levels of advanced 
glycation end products have a three-fold increased risk 
for renal disease and a seven-fold augmented risk for any 
complication (3-7).
 Hence, a drug that blocks advanced glycation end product 
formation blunts the rise in serum creatinine in patients 
with type II diabetes mellitus and progressive chronic 
renal failure, approving the beneficial effects of advanced 
glycation end product reduction (4-8).
Sevelamer carbonate has shown to reduce HbA1c, 
advanced glycation end-products, lipids, and TNFα by 
reduced inflammation and oxidative stress in stage 2-4 
diabetic chronic kidney disease (2-7). 
Additionally, fibroblast growth factor 23 , serum phosphate 
and calcium reduced by sevelamer carbonate, in various 
studies, while fibroblast growth factor 23 is associated with 
cardiovascular disease and vascular calcification in dialysis 
and diabetic patients. Furthermore, sevelamer carbonate 
also diminishes LDL-C and improves insulin resistance. 
Sevelamer also reduces coronary artery calcification in 
patients on hemodialysis (2-7). 
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Retinal vascular changes are associated with hypertension 
and diabetes and can predict clinical cardiovascular events 
consisting myocardial infarction in individuals with 
diabetes. Investigations had shown that microvascular 
disease in the retina, named as retinopathy signs, is 
accompanied with subclinical coronary macrovascular 
disease, encountered as increased coronary calcification, 
independently of age, gender, race or ethnicity, blood 
pressure, and other traditional and nontraditional risk 
factors (4-7). Likewise it was found that diabetic individuals 
with retinopathy had significantly higher coronary artery 
calcification intensity than diabetic subjects without 
retinopathy. Hence the association of retinopathy with 
coronary artery calcification supports the idea that, the 
same pathophysiological processes may relate to both 
macrovascular and microvascular diseases. Therefore, 
it has possible that sevelamer abolishes progression of 
vascular calcification, and affects inflammatory markers, 
LDL-C, and consequently decrease the incidence of 
retinopathy in diabetic patients who suffer from high 
blood pressure (4-7).
 The rationale behind this hypothesis is, a direct influence 
of sevelamer on microvasculature via inflammatory 
markers, LDL-C and phosphorus reducing capability. An 
indirect influence on microvasculature as a result of large 
vessels calcification diminution and finally an indirect 
eefct influence through hypertension (3-8).
Many individuals with diabetes have concomitant 
nephropathy. In patients with chronic renal failure, 
sevelamer is administered in the management of 
hyperphosphatemia. In a recent study, sevelamer was 
detected to lower HbA1c, triglycerides and total cholesterol. 
The mechanism behind of this effect of sevelamer on HbA1c 
is ill-understood. Sevelamer is likewise a bile sequestrant in 
addition to being a phosphate binder. Hence, it is possible 
that, this effect of sevelamer on HbA1c be related to its bile 
acid–binding ability (3-8).
Sevelamer augments the delivery of bile acids to the 
distal colon via its bile sequestration capability, thereby 
promoting glucagon-like peptide 1(GLP-1) release and 
modulating HbA1c (3-6).
Recent clinical and preclinical investigations have detected 
glucose and lipid-lowering effects of sevelamer, which 
imply the role of this drug in the treatment of type II 
diabetic patients. These properties possibly derived from 
the bile acid-binding efficacy of sevelamer (4-9). 
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